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The mechanisms underlying pathophysiological regulation of tissue macrophage (Mϕ)
subsets remain poorly understood. From the expression of 207 Mϕ genes comprising 31
markers for 10 subsets, 45 transcription factors (TFs), 56 immunometabolism enzymes,
23 trained immunity (innate immune memory) enzymes, and 52 other genes in microarray
data, we made the following findings. (1) When 34 inflammation diseases and tumor
types were grouped into eight categories, there was differential expression of the 31
Mϕ markers and 45 Mϕ TFs, highlighted by 12 shared and 20 group-specific disease
pathways. (2) Mϕ in lung, liver, spleen, and intestine (LLSI-Mϕ) express higher M1 Mϕ
markers than lean adipose tissue Mϕ (ATMϕ) physiologically. (3) Pro-adipogenic TFs
C/EBPα and PPARγ and proinflammatory adipokine leptin upregulate the expression
of M1 Mϕ markers. (4) Among 10 immune checkpoint receptors (ICRs), LLSI-Mϕ and
bone marrow (BM) Mϕ express higher levels of CD274 (PDL-1) than ATMϕ, presumably
to counteract the M1 dominant status via its reverse signaling behavior. (5) Among
24 intercellular communication exosome mediators, LLSI- and BM- Mϕ prefer to use
RAB27A and STX3 than RAB31 and YKT6, suggesting new inflammatory exosome
mediators for propagating inflammation. (6) Mϕ in peritoneal tissue and LLSI-Mϕ
Lai et al. Novel Macrophage Pathways in Disease
upregulate higher levels of immunometabolism enzymes than does ATMϕ. (7) Mϕ from
peritoneum and LLSI-Mϕ upregulate more trained immunity enzyme genes than does
ATMϕ. Our results suggest that multiple new mechanisms including the cell surface,
intracellular immunometabolism, trained immunity, and TFs may be responsible for
disease group-specific and shared pathways. Our findings have provided novel insights
on the pathophysiological regulation of tissue Mϕ, the disease group-specific and shared
pathways of Mϕ, and novel therapeutic targets for cancers and inflammations.
Keywords:macrophages, disease-specific and shared pathways, immune checkpoint receptors, trained immunity,
immunometabolism pathways
INTRODUCTION
As we reported previously (1–5), monocytes and macrophages
(Mϕ) play significant roles in driving cardiovascular
inflammations induced by various metabolic cardiovascular
disease-related danger-associated molecular patterns (DAMPs)
such as hyperlipidemia, hyperglycemia, hyperhomocysteinemia,
and chronic kidney disease. Also, monocyte and Mϕ
differentiation during various metabolic cardiovascular diseases
has been characterized (5). In recent years, a complicated
relationship between the bone marrow, monocytes/Mϕ, and
the development of atherosclerotic plaques has begun to be
revealed (6). The roles of Mϕ in modulating foam cell formation
(7) and inflammation resolution (8) have also been reported.
Moreover, several additional developments have been made,
including in tissue Mϕ characterization, Mϕ polarization, subset
characterization (9), clonal production, and trained immunity
(trained immunity) (10). A recent success on the CANTOS
trials with anti-interleukin-1β (IL-1β) monoclonal antibody
Canakinumab (11) further emphasized the significant roles
of inflammatory cytokines in the pathogenesis of metabolic
cardiovascular diseases, in which monocytes and Mϕs secrete
cytokines in large numbers and amounts in response to the
stimulation of DAMPs or conditional DAMPs that we had
reported (12). However, the molecular mechanisms underlying
several vital aspects of Mϕ remain poorly determined: (1) the
expression of Mϕ markers and Mϕ transcription factors, (2)
pathways in the regulating roles of Mϕ in various diseases,
Abbreviations: TFs, transcription factors; LLSI, lung, liver, spleen, and intestine;
Mϕ, Macrophages; DAMPs, danger associated molecular patterns; IL-1β,
interleukin-1β; ATMϕ, adipose tissues Mϕ; BM, bone marrow; Treg, regulatory
T cell; APC, antigen presenting cell; STAT1, signal transducer and activator
of transcription 1; NCBI, National Center for Biotechnology Information; LPS,
lipopolysaccharide; IFN-γ, interferon- γ; IL-4, interleukin-4; TGF-β, transforming
growth factor- β; IL-1Ra, IL-1 receptor antagonist; MHO, metabolically healthy
obese; KLF, Krüppel-like family; C/EBPα, CCAAT/enhancer-binding protein α;
PPARγ, peroxisome proliferator-activated receptor γ; CXCL10, C-X-C motif
chemokine 10; STAB1, stabilin 1; F13A1, coagulation factor XIII A chain; Chil4,
chitinase-like 4; ARG1, arginase 1; SFRP5, secreted frizzled-related protein 5;
PDL1, programmed death-ligand 1; FoxO, Forkhead box O; PD-L1, programmed
death ligand 1; PPP, pentose phosphate pathway; IPA, Ingenuity Pathway Analysis;
STX3, syntaxin 3; VAT, visceral adipose tissue; IRF4, interferon regulatory factor 4;
MARE,Maf recognition elements; Tfh, follicular T helper cell; PAMP-Rs, pathogen
associated molecular pattern receptors; DAMP-Rs, danger associated molecular
pattern receptors; irAEs, immune-related adverse effects; mAb, monoclonal
antibody; TAMs, tumor associated macrophages.
and (3) the differentiation and transdifferentiation of tissue
Mϕ subsets.
Macrophages play significant roles in the pathogenesis of
various diseases including cardiovascular (13), metabolic (14),
infectious (15), respiratory (16), digestive (17), autoimmune (18),
and many types of cancers (19, 20). However, three important
questions remain: whether Mϕ use the same pathways and play
the same roles or whether they use disease-specific pathways and
play disease-specific roles in addition to the shared roles and
pathways; whether 10Mϕ subset markers and newly identified 27
TFs (21) and other 18 Mϕ subset TFs are differentially expressed
in tissues; and whether all these newly reported proinflammatory
features of Mϕ are differentially expressed in various tissues.
Addressing these issues will improve our understanding of the
disease-specific and shared roles and pathways of Mϕ in the
pathogenesis of various diseases and cancers and will lead to
the identification of novel therapeutic targets specific to those
diseases and cancers.
Determining novel mechanisms underlying macrophage
disease-specific and shared pathways first requires an
understanding of how macrophages respond to environmental
and tissue functional cues from several aspects such as
cell surface receptor signaling, cell-cell interaction receptor
signaling, cell-cell communication signaling, intracellular
immunometabolic pathways, and transcription factors.
Macrophages are present in almost all tissues of the body,
displaying distinct location-specific phenotypes and gene
expression profiles (22). In addition to central roles in innate
immunity and as modifiers of the adaptive immune responses,
tissue Mϕ play supportive functions to the tissues they reside in
Hoeksema and Glass (13).
Several cell-surface-specific mechanisms could promote
macrophage heterogeneity. First, by varying stimuli such as
different cytokines or DAMPs to act on Mϕ cell surface
receptors, Mϕ can be “polarized” into as many as total 10
macrophage subsets including the typical proinflammatory M1
Mϕ and anti-inflammatory M2 Mϕ (9). Also, as many as
28 T cell co-stimulation receptors and co-inhibition/immune
checkpoint receptors as cell-cell contact signaling receptors
may serve as a second cell surface mechanism to shape
the antigen-presenting functions of Mϕ (23). Finally, recent
reports showed that exosomes are local and distal cell-cell
communication vehicles (24), which may serve as the third
cell-surface mechanism.
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We also reported that exosomes secreted from immune
cells such as macrophages might propagate inflammation from
the first inflamed cells to the secondary inflammatory cells
(25); exosomes regulate inflammation and immune responses
via intercellular exosome communications (26). In addition
to cell surface mechanisms, the M1 Mϕ proinflammatory
metabolic pathways and M2 metabolic pathways have been
identified (27) as the intracellular mechanisms. Another
development is the recognition of innate immune memory
(trained immunity) pathways such as increased glycolysis
pathway, enhanced acetyl-CoA (activated acetate, cellular acetyl
donor) generation, and increased expression of mevalonate
pathway enzymes (28, 29), which were “zoomed in” to
through extensive metabolic remodeling of 2,722 experimentally
elucidated pathways (https://metacyc.org). Recent reports also
identified numerous transcription factors involved in Mϕ
differentiation and Mϕ subset polarization.
Regardless of significant progress in the field, several
important questions remain. The first is whether, under
various disease conditions, Mϕ uses both disease-specific
signaling pathways and shared pathways. To determine
the molecular mechanisms underlying disease-specific and
shared pathways of macrophages, we examined macrophage
features from tissue-specific differential expression of Mϕ cell
surface markers, transcription factors, Mϕ cell-cell contact
signaling receptors (T cell co-stimulation receptors and
co-inhibition/immune checkpoint receptors), Mϕ cell-cell
communication vesicle–exosome biogenesis and docking
machinery, and Mϕ intracellular metabolism pathways such
as bioenergy metabolism pathways and trained immunity
(innate immune memory) pathways. We then narrowed in
on the following questions: whether tissues have differential
expression of Mϕ subset markers and transcription factors,
whether tissue Mϕ have different inflammatory and trained
immunity (innate immune memory) potentials, and whether
tissue Mϕ have different bioenergy metabolism pathways
and trained immunity pathways. To address these issues, we
determined the expression of 207 Mϕ genes in several tissues
such as lung, liver, intestine, spleen, and bone marrow-derived,
including 10 subset markers, 45 transcription factors (TFs),
and 127 other regulatory genes by analyzing the microarray
experimental data sets that other investigators deposited in
the NIH-NCBI GEO DataSets database, as shown in Figure 1.
Of note, we pioneered this type of novel experimental data
mining analysis in 2004 (30), which has allowed us to generate
original findings and novel hypotheses for our experimental
projects. The significant differences between our experimental
database mining approaches and traditional literature reviews
are detailed in Table 1. Based on the expression changes of
31 ten-Mϕ-subset markers and 45 TFs in eight groups of a
total of 34 diseases, including 10 types of cancers, we have
identified 20 novel disease group-specific and 12 new shared
macrophage pathways. In addition, we also found new signaling
and metabolic pathways underlying tissue Mϕ subset regulation
in pathophysiological conditions as novel mechanisms for Mϕ
heterogeneity, which serve as novel therapeutic targets specific
to cancers and inflammations.
RESULTS
Expression of 31 Mϕ Markers and 45 Mϕ
TFs Is Modulated in Eight Groups of a Total
of 34 Diseases, Including 24 Inflammatory
Organ Diseases and 10 Types of Cancers;
and Both Shared and Disease-Specific
Pathways for Each Group of
Disease/Tumor Have Been Identified
Mϕ play a key role in the pathogenesis of various diseases.
However, two critical questions remain: whether Mϕ use the
same pathways and play the same roles or whether they
use disease-specific pathways and play disease-specific roles
in addition to the shared roles and pathways. To improve
our understanding of the roles of Mϕ in various diseases,
we examined the expression of 31 Mϕ subset markers and
45 Mϕ transcription factors (Table 2) in eight groupings of
a total of 34 diseases, including four types of autoimmune
diseases, four types of cardiovascular diseases, four types of
digestive diseases, four types of infectious diseases, four types
of metabolic diseases, four types of respiratory diseases, five
types of digestive cancers, and five types of other cancers.
As shown in Table 3A, some Mϕ markers were upregulated
in more than 30% of the 34 diseases, including three M1
markers, CXCL11, CXCL10, and CXCL9, 2 M2 markers, CCL18
and IL1RN, and one M4 marker, MMP7, suggesting that
these markers may play significant roles in the pathogenesis
of the diseases. In addition, the diseases with Mϕ markers
upregulated in more than 30% of the 34 diseases were of eight
types, including #5 myocardial infarction, #6 coronary artery
disease, #10 gastritis, #11 Crohn’s ileitis, #12 Crohn’s colitis,
#29 esophageal cancer, #32 ovarian carcinoma, and #34 renal
carcinoma, suggesting that these diseases may have significant
Mϕ marker activities with the pathogenic processes. Moreover,
as shown in Table 3B, some Mϕ transcription factors (TFs) were
upregulated in more than 30% of the 34 diseases, including M1
TF STAT1 and three other Mϕ TFs such as HMGA1, E2F3,
and NME1, suggesting that these TFs play significant roles
in the pathogenesis of the diseases. Furthermore, the diseases
having Mϕ TFs upregulated in more than 30% among the 34
diseases were of six types, including #6 coronary artery disease,
#12 Crohn’s colitis, #28 hepatocellular cancer, #29 esophageal
cancer, #32 ovarian carcinoma, and #33 lung cancer, suggesting
that these diseases have significant Mϕ TF activities with the
pathogenic processes.
We then determined whether there are disease-specific
signaling pathways and shared pathways based on the expression
changes of Mϕ subset markers and Mϕ TFs in eight groups
of 34 diseases and tumors. After analyzing the Ingenuity
Pathway Analysis results of the top 10 pathways in both
upregulated and downregulated Mϕ subset markers and Mϕ
TFs, respectively, we compared all the upregulated pathways,
downregulated pathways, and the pathways either upregulated
or downregulated in some diseases (upper panel, middle panel,
and lower panel of Tables 3C,D). As shown in Table 3C,
we found three disease-specific pathways upregulated and 14
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FIGURE 1 | Flow chart of database mining strategy and two parts of data organization. (I) database mining strategy was used to analyze the macrophage (Mϕ)
marker tissue expression profiles in physiological conditions. (II) Mϕ marker and Mϕ transcription factor expression changes were analyzed on experimental data from
the microarray datasets in different diseases. NIH-Geo website: www.ncbi.nlm.nih.gov/geo/; GEO2R website: www.ncbi.nlm.nih.gov/geo/geo2r/. Mϕ,
macrophages; TFs, transcription factors; T-reg, CD4+ regulatory T cell; KO, knock out; WT, wild type; ATMϕ, adipose tissue macrophage; M1, type I macrophage;
M2, type 2 macrophage.
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TABLE 1 | A novel research publication type utilizing big-omics experimental database mining analyses leads to original new findings and generates new hypotheses.
Category Big-omics
database mining
Traditional literature
review
Analysis of experimental data (NIH Geo DataSets with microarray experimental data, etc.) Yes No
Original new findings Yes No
Association research (gene co-expression patterns at the same pathology or stimuli) Yes No
Causative research (upstream regulator gene-deficient microarrays, …) Yes No
Panoramic view at multiple mechanisms and pathways Yes Yes
Improvement of our understanding Yes Yes
Searchable database requirements and tools Yes No
New publication types after–omics and high throughput experimental data generation Yes No
Different focuses from original papers Yes No
Use of Ingenuity Pathway Analysis (IPA) to analyze experimental data Yes No
Bioinformatic prediction No No
Future experimental verification Yes Yes
Face the low-throughput problems in verifying high-throughput–omics data (also see Yao et al.
Nature Immunology, PMID: 31209400)
Yes No
Summary of previous reports No Yes
Example for our database mining paper on IL-35 (highly cited by 173 papers) PMID: 22438968
Example for traditional literature review: a Nature Immunology review that cited our database
mining paper on IL-35
PMID: 22990890
Our experimental papers verifying the findings originated from our database mining paper on
IL-35
PMIDs: 26085094;
29371247
Use of multiple NIH databases including PubMed database (https://www.ncbi.nlm.nih.gov/
books/NBK143764/)
Yes No
PubMed database only
Comparisons were made regarding various aspect between this study, with a big-omics experimental database mining approach, and traditional literature reviews.
disease-specific pathways downregulated. As shown in Table 3D,
we found 16 disease-specific pathways upregulated and 16
disease-specific pathways downregulated. We also compiled a
list of pathways that are shared in several groups of diseases
and tumors.
As shown in Table 3A, we found that among 21 disease-
upregulated pathways, one pathway communication between
innate and adaptive immune cells is shared among eight groups
of diseases. We also found that three pathways, namely the role
of hypercytokinemia/hyperchemokinemia in the pathogenesis of
influenza, agranulocyte adhesion and diapedesis, and granulocyte
adhesion and diapedesis, are shared by seven groups of diseases;
four pathways, namely differential regulation of cytokine
production in Mϕ and T helper cells by IL-17A and IL-17F, IL-
10 signaling, the role of cytokines in mediating communication
between immune cells, and pathogenesis of multiple sclerosis,
are shared by 7 groups of diseases; and one pathway, altered
T cell and B cell signaling in rheumatoid arthritis, is shared
by five groups of diseases. In contrast, as shown in Table 3B,
among 42 disease-downregulated pathways, 22 (52%) pathways
are shared by two or more groups of disease, and 20 disease-
specific downregulated pathways may be important for the
pathogenesis of the diseases. Furthermore, as shown in Table 3C,
13 Mϕ pathways are upregulated and/or downregulated in
some disease groups in two different directions, suggesting
that some Mϕ functional pathways are modulated in disease-
specific manners.
These results suggest that the expression changes of Mϕ
TFs in eight groups of 34 diseases are more disease-
specific than that of Mϕ subset markers, allowing the
identification of 20 disease-specific and 12 shared (more than
4 groups of diseases) modulations of Mϕ TFs pathways
in eight groups of 34 diseases. As shown in Table 3E, in
detail, we found five upregulated disease-specific pathways
in autoimmune diseases, three upregulated disease-specific
pathways in cardiovascular diseases, two upregulated disease-
specific pathways in digestive inflammatory diseases, four
upregulated disease-specific pathways in infectious diseases,
one disease-specific pathway in metabolic disease, one disease-
specific pathway in respiratory disease, one upregulated pathway
(shared with autoimmune disease) and one downregulated
specific pathway in digestive tumors, and two upregulated
disease-specific pathways in other tumors. In addition, we found
12 pathways that are shared by more than four groups of diseases
and tumors. These results demonstrate for the first time that the
expressions of Mϕ TFs are modulated in both disease-specific,
and shared signaling pathways; these results provide insights
on the roles of Mϕ in various diseases and novel therapeutic
targets for modulating Mϕ TFs and Mϕ functions for those
diseases and tumors. These results have also demonstrated for
the first time that certain “high hierarchical” functional pathways
in pathological Mϕ are more important in the pathogenesis
of various diseases than other pathways, making them novel
pathological Mϕ-specific therapeutic pathways; disease-specific
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TABLE 2 | A total of 207 macrophage (Mϕ)-related regulator genes in seven representative groups were studied in this paper, including 31 Mϕ subset marker genes, 18
Mϕ subset transcription factor genes (TF), 27 Mϕ general transcription factor genes, 28 T cell co-stimulation and co-inhibition receptor genes, 56 bioenergetics pathway
enzyme genes, 23 trained immunity (innate immune memory) pathway genes, and 24 exosome biogenesis/docking mediator genes.
Category Type Gene list Number Total
number
PMID Note
Mϕ markers (cell surface) M1 IL1B, TNF, IL6, CXCL11, CXCL10, CXCL9,
IL23A, IL12A, IL12B, ARG2
10 43–12 = 31 24998279 Detailed
information see
Figure S1M2a MRC1, CD163, STAB1, CCL18, CD200R1,
F13A1, IL1RN, ARG1, PDE4DIP, Chil4, Chil3,
Retnla
12
M2b IL10, IL12B, IL12A 3
M2c MRC1, ARG1 2
M2d TNF, IL12A, IL12B 3
M4 MMP7, MRC1, S100A8 3
Mox HMOX1, NFE2L2, TXNRD1, SRXN1 4
M(hb) CD163, MRC1 2
Mhem CD163 2
HA-mac CD163, HLA-DRB1, HLA-DRA 3
Mϕ TFs M1 HIF1A, RELA, IRF3, STAT1, STAT2 5 19–1 = 18 25228902
25506346
28228760
23640482
25505468
26954942
26972048
25755062
25367649
Detailed
information see
Figure S2
(41⋆) (nuclear proteins) M2a PPARD, PPARG, KLF4, AKT1 4
M2b MAPK1, STAT3 2
M2c NFKB1, NFKB2, NR3C1, NFE2 4
M2d N/A 0
M4 N/A 0
Mox NR1H3 1
M(hb) ATF1 1
Mhem NR1H3, NR1H2 2
HA-mac N/A 0
General Mϕ TFs CREB1, HMGA1, SMAD4, ZNF148, HBP1,
CKLF, ZNF281, FOXO3, HEY1, ETS2, HIF1A,
STAT4, MELTF, BATF3, NFE2, NFKB1, RIT1,
HIVEP1, JUNB, NFX1, FOXN3, STAT3,
PWWP3A, MXD4, E2F3, CEBPD, NME1
27 27 24530056
Co-stimulation and
co-inhibition receptors
(cell-cell interaction
receptors)
Co-stimulation
receptors
ICOSLG, CD70, TNFSF14, CD40, TNFSF9,
TNFSF4, TNFSF15, TNFSF18, TNFSF8,
TIMD4, SLAMF1, CD48, SEMA4A, CD58
14 28 23470321
27192563
Detailed
information see
Figure S3
Co-inhibition receptors LGALS9, NECTIN3, TNFRSF14, PDCD1LG2,
CD274, CD276, VTCN1, VSIR, HHLA2, BTNL2
10
Dual-function receptors CD80, CD86, PVR, IL2RB 4
Bioenergetics pathway
enzymes (intracellular
metabolism
I-immunometabolism)
TCA cycle CS, ACO1, ACO2, IDH2, IDH3A, OGDH,
SUCLA2, SUCLG1, SUCLG2, SDHA, SDHB,
FH, MDH2
13 56 23317369
25945836
26024507
25594225
Detailed
information see
Figure S4
Pentose phosphate
pathway
G6PD, PGLS, PGD, RPE, RPI, TALDO1, TKT 7
Glutamine pathway SLC38A1, SLC38A2, GLS1, GLUD1, GOT2,
GPT2, SLC1A5
7
Fatty Acid synthesis
pathway
FATP, CD36, SLC27A1, SLC27A2, SLC27A3,
SLC27A4, SLC27A5, SLC27A6, ACSL1,
ACSL3, ACSL4, ACSL5, ACSL6, CPT1A,
CPT1B, CPT2
16
(Continued)
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TABLE 2 | Continued
Category Type Gene list Number Total
number
PMID Note
Fatty Acid B-oxidation
pathway
ACADVL, HADHA, HADHB, ACADS, ACADSB,
ACADM, ACADL, ACAD8, ACAD9, ACAD10,
ACAD11, ECHS1, HADH
13
Trained immunity pathway
enzymes (intracellular
metabolism II-trained
immunity)
Glycolysis pathway GLUT1, HK, GPI, PFK1, ALDOA, TPI1,
GAPDH, PGK, PGAM, ENO, PK, LDH, PDH1,
MPC1
14 24–1 = 23 24911170
30298120
25594225
Detailed
information see
Figure S5
Mevalonate
metabolism pathway
ACLY, HMGCS1, HMGCR, MVK, PMVK, MVD,
FDPS
7
Acetyl-CoA generating
enzyme
ACLY, ACSL1, ACSL5 3
Exosome
biogenesis/docking
mediators (local and distal
cell-cell communication
vehicles)
Biogenesis mediators RAB11A, STX6, ARF6, RAB27A, RAB31,
SEC22B, STX18, STX3, VAMP3, YKT6,
TSG101, PDCD6IP
12 24 29109687 Detailed
information see
Figure S6
Docking mediators CAV1, CD44, SELE, ADGRE1, LGALS3,
LGALS1, ICAM-1, ITGA6, ITGB1, ITGB3,
ITGB4, LAMP1
12
Total number 207
Mϕ pathways are also important for the pathogenesis of the
diseases and are disease-specific therapeutic targets.
Macrophages (Mϕ) in Lung, Liver, Spleen,
and Intestine Express Higher M1 Mϕ
Markers Than Lean Adipose Tissue in
Physiological Conditions
To determine the novel mechanisms underlying disease-specific
and shared macrophage pathways, we and others previously
reported that metabolic disease risk factors serve as conditional
danger-associated molecular patterns (conditional DAMPs)
(12, 31, 32) and induce monocyte/Mϕ differentiation into
Ly6Chigh-(1-3) and CD40+ proinflammatory monocytes (4),
and accelerate vascular inflammation. Other studies also reported
that, under certain experimental conditions such as stimulation
with lipopolysaccharide (LPS) and interferon-γ (IFN-γ) for
M1 polarization or interleukin-4 (IL-4) for M2 polarization
(33), Mϕ can be polarized into multiple subsets including
proinflammatory M1 and M4 Mϕ, anti-inflammatory M2,
M(Hb), and Mhem Mϕ (34) (Figure 2A). However, whether
the different physiological environments present in tissues
affect the expression of residential Mϕ subsets markers and
other regulators has not been studied (35). We hypothesized
that various tissue environments with tissue differentiation
potentials, DAMPs/conditional DAMPs, cytokines, and cell-
cell contacts induce differential expression patterns of Mϕ
subset markers.
To examine this hypothesis in a very comprehensive manner,
we collected 31 Mϕ markers of 10 Mϕ subsets, as reported
in a recent publication (9) (Table 2). As summarized in
Figure 2A, the 10 Mϕ subsets perform various functions in
regulating inflammation, immune responses, anti-oxidant, and
tumor promotion (9). We included 10 Mϕ markers in our
analysis, and these markers are differentially expressed in
different Mϕ subsets. Furthermore, we also made a list of
the transcription factors (TFs) of 18 Mϕ subsets, which are
critical for the development and maintenance of seven out of
10 Mϕ subsets (Table 2). The data for TFs that are critical for
development of M2d, M4, and HA-Mac were not available at
the time we conducted the analysis. Moreover, we included an
additional 27 Mϕ TFs that were identified in Mϕ by RNA-Seq
analysis (21).
By examining the expression of these Mϕ regulators in Mϕ
microarray datasets deposited in the NI-NCBI GEO DataSets
database (https://www.ncbi.nlm.nih.gov/gds/), we found that the
expression of M1 Mϕ markers is higher in Mϕ that reside in
tissues such as lung, liver, spleen, and intestine (LLSI) compared
to lean adipose tissue Mϕ (ATMϕ), physiologically (Figure 2B).
This suggests that the majority of lung, liver, spleen, and intestine
(LLSI) residential Mϕ are M1 Mϕ (Figure 2C); therefore, these
tissues have more potential to produce inflammatory responses
than adipose tissue. In addition, as shown in Figures 2B,D, we
found that: (1) Retnla, CD163, and MRC1 are relatively ATMϕ-
specific markers; (2) STAB1, NFE2L2, and SRXN1 are relatively
bone marrow (BM)-specific Mϕmarkers; (3) ARG1 is a relatively
specific Mϕ marker for peritoneum, M2a, and M2c; (4) Chil4 is
a relatively specific Mϕ marker for lung and M2a; (5) IL1B is
a relatively specific Mϕ marker for liver and M1; (6) PDE4DIP
and HMOX1 are relatively specific Mϕ markers for spleen, M2a,
and MOX; and (7) CXCL9 is a relatively specific Mϕ marker for
small intestine and M1. Our results suggest that these Mϕ subset
markers modulated in the tissues may play important roles in
tissue-specific Mϕ functions and subset compositions.
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TABLE 3E | Twenty new disease group-specific and 12 shared (more than 4
groups of diseases) Mϕ reprogramming pathways have been identified in eight
groups of 34 diseases and tumors.
A. Specific pathways (upregulated except #; unique for each group
of diseases)
Autoimmune diseases Role of JAK1 and JAK3 in γc Cytokine Signaling
CNTF Signaling
Thrombopoietin Signaling
EGF Signaling
GM-CSF Signaling
Cardiovascular
diseases
IL-17A Signaling*
NRF2-Mediated Oxidative Stress Response
Parkinson’s Signaling
Digestive inflammatory
disease
VDR/RXR Activation#
FXR/RXR Activation#
Infection disease Cyclins and Cell Cycle Regulation
Cell Cycle Regulation by BTG Family Proteins
Estrogen-mediated S-phase Entry
Role of CHK Proteins in Cell Cycle Checkpoint
Control
Metabolic diseases Notch Signaling
Respiratory disease Adrenomedullin signaling pathway
Digestive tumors Oncostatin M Signaling
Cancer Drug Resistance By Drug Efflux (#,
downregulated)
Other tumors IL-15 Production
Role of PKR in Interferon Induction and Response
B. Shared pathways (upregulated and shared by more than four major
disease groups)
Altered T Cell and B Cell Signaling in Autoimmune Disease
Differential Regulation of Cytokine Production in Macrophages and T Heiper
Cells by IL-17A and IL-17F
Neuroinflammation
Signaling Pathway
Graft-vs.-Host
Disease Signaling
IL-10 Signaling
Role of Cytokines in Mediating Communication between Immune Cells
Communication between Innate and Adaptive Immune Cells
Role of Hypercytokinemia/Hyperchemokinemia in the Pathogenesis of Disease
FLT3 Signaling in Hematopoietic Progenitor Cells
ERK/MAPK Signaling
JAK/Stat Signaling
Role of JAK1, JAK2 and TYK2 in Interferon Signaling
*Some of the pathway names were simplified to avoid potential confusion.
Pro-adipogenic Transcription Factors
C/EBPα and PPARγ, and Proinflammatory
Adipokine Leptin Upregulate the
Expression of M1 Mϕ Markers
Adipose tissue releases more than 50 hormones, cytokines, and
chemokines, collectively called adipokines, which regulate several
physiological processes concerning energy, glucose metabolism,
and immunity in an autocrine, paracrine, or systemic manner as
well as several pathological processes including proinflammatory
or anti-inflammatory processes, thereby contributing to insulin
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resistance and other inflammations (36). Adipose tissue from
lean individuals releases anti-inflammatory adipokines such
as adiponectin, transforming growth factor-β (TGF-β), IL-10,
IL-4, IL-13, IL-1 receptor antagonist (IL-1Ra), and apelin.
In contrast, obese adipose tissue secretes proinflammatory
cytokines such as tumor necrosis factor-α (TNF-α), IL-
6, leptin, visfatin, resistin, angiotensin II, and plasminogen
activator inhibitor 1 (37). About one-third of obese adults
and 10% of non-obese adults are metabolically healthy obese
(MHO) (38, 39). A series of reports suggest that patients
with metabolically healthy obesity (MHO) have significantly
higher rates of type II diabetes (40), metabolic syndrome (41),
and chronic kidney disease (42) than metabolically healthy
lean individuals. The molecular mechanisms underlying the
pathogenesis of MHO remained poorly determined. In the search
for master regulators responsible for MHO with the features
of being pro-inflammatory/proatherogenic but anti-adipogenic,
we reported that microRNA-155 (miR155) and, potentially,
microRNA-221 are such master regulators for MHO(44).
Deficiencies in those master regulators such as miR155 in an
atherogenic apolipoprotein E (ApoE)−/− background led to
the establishment of MHO in mice, significantly improving
our understanding of the molecular mechanisms underlying
MHO (43). Our recent findings further suggest that elevated
adipokine resistin and leptin in a miR155−/−/ApoE−/− MHO
model fed a high-fat diet for 12 weeks may serve as a driver
for the newly termed “second wave of inflammation status”
in the MHO model (44). Along the same line, the issue of
whether proinflammatory adipokines secreted by obese adipose
tissues promote the expression of M1 Mϕ markers and other
proinflammatory regulators remained poorly defined.
We hypothesize that proinflammatory cytokine interferon-γ
(IFN-γ) and lipopolysaccharide (LPS) upregulate M1 markers
and regulators but not M2 (45). To test this hypothesis, we
examined the expression of Mϕ markers and Mϕ TFs involved
in M1 and M2 Mϕ polarization. As shown in Table 4A, when
we examined the TF expression in the Mϕ polarization from
human CD14+ monocytes, we made the following important
findings: (a) M1 polarization promotes the expression of
the Mϕ TFs for M1 and surprisingly also for M2c (IL-10
polarization); (b) the Krüppel-like family of transcription factor 4
(KLF4) was upregulated explicitly during M2a polarization (IL-4
polarization); and (c) four proinflammatory TFs (STAT1, STAT2,
STAT3, and NF-kB) are more upregulated in M1 than in M2
polarization, suggesting their importance in promoting M1 Mϕ
polarization (46).
In addition, as shown in Table 4B, we also determined
whether pro-adipogenic TFs, proinflammatory, and anti-
inflammatory adipokines can regulate Mϕ subset marker
expression. The results showed the following. (1) pro-adipogenic
TFs CCAAT/enhancer-binding protein α (C/EBPα) and
peroxisome proliferator-activated receptor γ (PPARγ) promote
the expression of M1 markers interleukin-1β (IL-1β), tumor
necrosis factor-α (TNF-α), and C-X-C motif chemokine 10
(CXCL10), suggesting that during adipogenesis, pro-adipogenic
TF-mediated signaling mechanisms have the potential to
promote M1 subset polarization. Of note, previous reports found
that C/EBPα (47) and PPARγ (48) promote M2 polarization.
One of our explanations is that pro-adipogenic TFs C/EBPα
and PPARγ may tend to promote M2 in lean adipose tissues
but that, in hypertrophic obese adipose tissues, these TFs
may promote polarization of proinflammatory M1. Further
detailed transcriptomic studies will be required to address this
discrepancy. (2) C/EBPα suppresses the expression of the M2a
markers stabilin 1 (STAB1), coagulation factor XIII A chain
(F13A1), chitinase-like 4 (Chil4), and Chil3. (3) C/EBPβ also
suppresses the expression of the M2a marker arginase 1 (ARG1).
(4) Deficiencies in anti-inflammatory adopkines such as secreted
frizzled-related protein 5 (SFRP5) and adiponectin do not
change the expression markers of all 10 types of Mϕs, suggesting
that the anti-inflammatory regulation of these adipokines acts
via Mϕ composition modulation-independence mechanisms. (5)
Proinflammatory adipokine leptin promotes M1 marker gene
expression and inhibits the marker expressions of M2 and other
Mϕ subsets.
Tissue Mϕ From Lung, Liver, Spleen,
Intestine, and Bone Marrow (BM) Express
Higher Levels of T Cell Co-inhibition
Receptor CD274 (PDL-1) Among 10
Co-inhibition Receptors Than That of Lean
Adipose Tissues
Since Mϕs are prototypic professional antigen-presenting cells
(APCs) that modulate CD4+ T cell activation by providing T
cell activation signal #1 and co-stimulation/co-inhibition-based
signal #2(50), we also examined the expression of 28 T cell co-
stimulation and co-inhibition (immune checkpoint) receptors
(23), including 14 co-stimulation receptors, 10 co-inhibition
receptors, and 4 dual-functional (both co-stimulation and co-
inhibition) receptors in tissue Mϕ (Figure 3A), as we reported
previously (49). As shown in Figure 3A, we found that: (i) theMϕ
from LLSI express co-inhibition receptor CD274 (programmed
death-ligand 1, PDL1) in much higher levels than ATMϕ
and (ii) the Mϕ from peritoneum and ATMϕ express lower
levels of CD274 than BM Mϕ. It has been reported that
CD274 has significant reverse signaling activities (50). Antitumor
immune response-enhancing transcription factor Forkhead box
O (FoxO) inhibits CD274 expression (51), suggesting that
CD274 expression may be responsible via reverse signaling for
hiding immune response-enhancing features of tumor cells.
Also, CD274 signals via conserved intracellular sequence motif
“RMLDVEKC” inhibit JAK1-induced STAT3 activation and
overcome interferon-mediated cytotoxicity (50). To correlate
with the reported findings, our results suggest that: (i) peripheral
tissue Mϕ, including LLSI Mϕ, express higher levels of T cell
co-inhibition receptor CD274 than ATMϕ, to contribute to the
establishment of immune tolerance at physiological conditions;
and (ii) since our data suggested that LLSI tissue Mϕ are
more proinflammatory than other Mϕ, higher expression of
CD274 in LLSI Mϕ suggests that the high homeostatic and anti-
inflammatory functions of CD274 (programmed death-ligand
1, PD-L1) via its reverse signaling in Mϕ (52) may counteract
the tissue Mϕ proinflammatory status (Figure 3B) in addition
to CD274 inhibition of T cell activation via PD-1 (programmed
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FIGURE 2 | (A) Macrophages (Mϕ) can be polarized into 10 (potentially more) different subsets, and the markers and main functions of 10 Mϕ subsets are different
(PMID: 24998279; 25319333; 25973901). M1, M4, and Mox are proinflammatory while the rest of the Mϕ subsets are anti-inflammatory. (B) Mechanism I: The 10
macrophage (Mϕ) subset markers (30) are differentially expressed in macrophages from various tissues, and lung, liver, spleen, and small intestine upregulate more M1
Mϕ markers than M2 Mϕ markers in the physiologic condition in comparison to lean ATMϕ. (1) Retnla, CD163, and MRC1 are relatively adipose tissue-specific Mϕ
(ATMϕ) markers; (2) STAB1, NFE2L2, and SRXN1 are relatively bone marrow-specific Mϕ markers; (3) ARG1 is a relatively specific Mϕ marker for peritoneum, Chil4 is
a relatively specific Mϕ marker for lung, IL1B is a relatively specific Mϕ marker for liver, PDE4DIP and HMOX1 are relatively specific Mϕ markers for spleen, and CXCL9
is a relatively specific Mϕ marker for small intestine. (C) Mϕ subset markers are differentially expressed in various tissues. (D) Tissue Mϕ have different compositions of
Mϕ subsets as judged by the expressions of Mϕ subset markers. (1) The genes of macrophage subtypes such as Mhb, Mhem, and HA-mac are relatively adipose
tissue-specific. (2) The genes of Mox are bone marrow macrophage-specific. (3) Retnla is a M2a subset marker in peripheral tissues. (4) ILIB and CXCL9 are specific
markers for small intestine M1 macrophages. (5) ARG1 is a specific marker for peritoneal M2a and M2c macrophages.
cell death protein 1, CD279) binding-mediated forward signaling
(53, 54).
Tissue Mϕ From Lung, Liver, Spleen,
Intestine, and Bone Marrow Prefer to Use
RAB27A and STX3 Than RAB31 and YKT6
in Mediating Exosome Biogenesis and
Docking, Suggesting New Inflammatory
Exosome Markers and a New Inflammatory
Exosome Status
In addition to the above-discussed cell surface mechanisms
such as Mϕ markers and cell-cell interaction (co-stimulation
and co-inhibition/immune checkpoint) receptors, as cell-cell
communication mechanisms of Mϕ and other cell types,
exosomes can transport and deliver a large cargo of proteins,
lipids, and nucleic acids and can modify cell and organ
function. In addition to their key role as vehicles of intercellular
communication, exosomes are increasingly recognized as
biomarkers and prognosticators of disease (55). We reported that
exosomes might modulate inflammation and immune responses
(26) and propagate inflammation (25). We also examined the
expression levels of 12 exosome biogenesis mediators and 12
exosome docking mediators in the tissue Mϕs (Figure 4A).
The results in Figure 4A showed that Mϕ from peritoneum,
lung, liver, spleen, and small intestine prefer to use RAB27A
and syntaxin 3 (STX3) than RAB31 and YKT6 in mediating
exosome biogenesis and docking and that adipose tissue Mϕs
use more Rab31, YKT6, and LGALS1 in mediating exosome
biogenesis and docking. Of note, it has been reported that
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TABLE 4A | Mechanism II: M1 polarization promotes the expressions of M1-
and M2c-transcription factors (TFs; NFkB1, NFkB2, and NR3C1) but inhibits the
expression of M2a TF PPARg; M2 polarization specifically upregulates M2a TF
KLF4, and M1 macrophages (Mϕ) express higher levels of TFs, STAT1, STAT2,
STAT3, and NF-kB than M0 Mϕ.
GEO ID GSE85346
Comparision M1 vs. M0 M2a vs. M0 M2b vs. M0 M2c vs. M0
M1 TFs HIF1A 2.247
RELA 5.401
IRF3 2.132
STAT1 9.433 3.077
STAT2 3.353 1.787
M2a TFs PPARD
PPARG −14.550 −1.988
KLF4 4.123
AKT1
M2b TFs MAPK1
STAT3 5.058 1.699
M2c TFs NFKB1 4.065 1.787
NFKB2 8.639
NR3C1 2.439
NFE2
Mox TFs NR1H3
M(hb) TFs ATF1
Mhem TFs NR1H3
NR1H2
Up 9/18 1/18 3/18 1/18
Down 1/18 0/18 1/18 0/18
RAB27A-dependent exosome production inhibits chronic
inflammation and enables acute response to inflammatory
stimuli (56) and that microRNA-30c-2-3p regulates RAB31 and
functions as an oncogene in gastric cancer tumorigenesis and
development by interacting with glioma-associated oncogene
homolog 1(57). The results suggest that the differences in
exosome biogenesis and docking in tissue Mϕs may be related
to their proinflammatory functional status (Figure 4B) as we
reported previously (26), that Rab GTPases not only regulate the
pathogenesis of cancer and neurodegenerative diseases (58) but
may also regulate inflammation functions of Mϕ exosomes, and
that syntaxin 3-identified homozygous likely deleterious variant
(59) may regulate inflammatory Mϕ exosomes.
Levels of Immunometabolism Pathway
Enzymes Are Higher in Mϕ in Peritoneal,
Lung, Liver, Spleen, and Intestine Than in
Adipose Tissue Mϕ
Since Mϕ bioenergetics metabolism, as an immunometabolism
pathway (60), regulates their polarizations (61), we hypothesized
that tissue Mϕs from different tissues would have various
metabolic pathway enzyme genes expressed at different levels.
To test this hypothesis, we collected 59 metabolic enzymes
involved in six metabolic pathways including the tricarboxylic
acid (TCA) cycle (13 enzymes), pentose phosphate pathway
(Warburg-Limpam-Dickens cycle and phosphogluconate shunt,
7 enzymes), glutamine pathway (7 enzymes) (62), fatty acid
pathway (16 enzymes), fatty acid B-oxidation pathway (63) (13
enzymes), and fatty acid C pathway (9 enzymes), as shown in
Table 1. Of note, six genes overlapped in different bioenergetics
metabolic pathways. Comparing the Mϕ from peritoneal and
LLSI tissues with that of adipose tissues (Figure 5A), we
found that 2 out of 13 TCA cycle enzymes, 2 out of seven
pentose phosphate pathway enzymes, one out of seven glutamine
pathway enzymes, 7 out of 16 enzymes in the fatty acid pathway,
5 out of 13 regulators in the fatty acid β-oxidation pathway,
and 3 out of 9 fatty acid C pathway enzymes were upregulated.
We also found that 1 out of 13 TCA cycle enzymes, 1 out
of seven pentose phosphate pathway enzymes, four out of
seven glutamine pathway enzymes, and 2 out of 16 enzymes
in the fatty acid pathway were downregulated. In addition,
comparing the Mϕ from peritoneal, intestine, and adipose tissue
with that of bone marrow, we found that 1 out of 13 TCA
cycle enzymes, 1 out of seven pentose phosphate pathway
(PPP) enzymes, 2 out of seven glutamine pathway enzymes,
2 out of 16 enzymes in the fatty acid pathway, and 2 out
of 13 regulators in the fatty acid β-oxidation pathway were
upregulated and that 5 out of 13 TCA cycle enzymes, 1 out of
seven pentose phosphate pathway enzymes, three out of seven
glutamine pathway enzymes, 4 out of 16 enzymes in the fatty
acid pathway, 5 out of 13 enzymes in the fatty acid β-oxidation
pathway and 3 out of 9 fatty acid C pathway enzymes were
downregulated. These results suggest that Mϕ in peritoneal,
lung, liver, spleen, and intestine may upregulate bioenergetics
pathway enzyme expression more than in Mϕ in adipose tissue
Mϕ, where expression of the enzymes in the PPP pathway
and the three fatty acid pathways increased and expression
of glutamine pathway enzymes decreased. Surprisingly, BM-
derived Mϕ expresses higher bioenergetics pathway enzymes
than that of Mϕ in peritoneum, intestine, and adipose tissues.
As shown in Figure 5B, our Ingenuity Pathway Analysis (IPA)
showed that: (1) comparing all the differences among tissue
Mϕ from peritoneal, lung liver, spleen, intestine, adipose tissue,
and bone marrow, type II diabetes signaling is shared; (2) the
fatty acid activation pathway is also shared among three groups:
(a) upregulated genes in peripheral tissue Mϕ vs. ATMϕ; (b)
upregulated genes in peripheral tissue Mϕ vs. BM Mϕ; and (c)
downregulated genes in peripheral tissue Mϕ vs. BM Mϕ; and
(3) the fatty acid β-oxidation pathway is among the top pathways
shared by two groups of upregulated genes in Mϕ in peritoneal,
lung, liver, spleen, and intestine vs. ATMϕ and downregulated
genes in Mϕ in peritoneal, intestine and ATMϕ vs. BMMϕ.
Expression of Trained Immunity (Innate
Immune Memory)-Related Metabolic
Genes Is Higher in Mϕ From Peritoneum,
Lung, Liver, and Spleen Than in ATMϕ, and
the Expression of Trained
Immunity-Related Metabolic Genes Is
Higher in Mϕ From Peritoneum, Small
Intestine and Adipose Tissues Than in
Bone Marrow Mϕ
One of the major differences between the adaptive immune
system and innate immune systems is that the cells in the
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TABLE 4B | Proadipogenic transcription factors C/EBPa and PPARg promote the expression of M1 macrophage markers, C/EBPa and C/EBPb inhibit the expressions of
M2 macrophage markers, and higher expressions of Mhb, Mhem, and HA-mac subtype markers in adipose tissues may result from stimulation in adipose tissue
environments rather than that in adipogenesis.
Adipose transcription factors deficient Anti-inflammatory adopkine deficient Proinflammatory adipokine deficient
GEO ID GSE55760 GSE59585 GSE14004 GSE37514 GSE50183 GSE66073 GSE46320 GSE27017
Comparision C/EBPa KD C/EBPb KO PPARg siRNA SFRP5 KO adiponectin deficient APJ ko PAI-1 KO Leptin deficiency
M1 markers IL1B −1.641 2.204
TNF −1.651
IL6 2.703 −9.353
CXCL11
CXCL10 −1.801 −15.123
CXCL9 −2.723
IL23A
IL12A
IL12B
ARG2 1.612
M2a markers MRC1 7.143
CD163
STAB1 1.534 8.693
CCL18
CD200R1 12.597
F13A1 3.694 3.926 2.446
IL1RN 3.095
ARG1 1.582 3.675
PDE4DIP −13.880
Chil4 12.446
Chil3 11.791 2.351
Retnla −16.512
M2b markers IL10 −1.822
IL12B
IL12A
M2c markers MRC1 7.143
ARG1 1.582 3.675
M2d markers TNF −1.651
IL12A
IL12B
M4 markers MMP7
MRC1 7.143
S100A8 5.599 −9.351 2.345
Mox markers HMOX1 2.025
NFE2L2 1.647 −2.126
TXNRD1
SRXN1
M(hb) markers CD163
MRC1 7.143
Mhem markers CD163
HA-mac markers CD163
HLA-DRB1
HLA-DRA
Up 6/31 1/31 1/31 0/31 0/31 1/31 0/31 11/31
Down 2/31 0/31 4/31 0/31 0/31 1/31 0/31 4/31
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FIGURE 3 | Mechanism III: The macrophages (Mϕ) from lung, liver, spleen, and intestine have differences in the expressions of T cell co-stimulation receptors,
co-inhibition/immune checkpoint receptors, and dual-function receptors in comparison to that of ATMϕ. (A) First, Mϕ from lung, liver, spleen and intestine express
CD274 much higher than adipose tissue macrophages; second, the Mϕ from peritoneum and adipose tissue express lower levels of CD274 than that of bone marrow,
suggesting that decreased expression of CD274 is a remarkable feature of adipose tissue macrophages; third, lung Mϕ upregulates the expression of TNFSF9,
SEMA4A (co-stimulation), and PDCD1GL2 in comparison to lean ATMϕ; and fourth, liver Mϕ upregulates TIMD4 (co-stimulation) and CD86 (dual) in comparison to
lean ATMϕ. (B) The proposed model of A.
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FIGURE 4 | (A) Mechanism IV. Tissue macrophages (Mϕ) have differences in the expression of several mediators for exosome biogenesis and docking. First, Mϕ
from peritoneum, lung, liver (STX3), spleen, and small intestine prefer to use RAB27A and STX3 than RAB31 and YKT6 in mediating exosome biogenesis and CD44
for docking in comparison to lean ATMϕ. In addition, Mϕ from lung also upregulates STX6 (biogenesis), CAV1, and LGALS3 (docking) comparing to lean ATMϕ.
Moreover, Mϕ from peritoneum and intestine upregulate ITGA6 for docking in comparison to lean ATMϕ. (B) Mϕ from peritoneum, lung, liver (STX3), spleen, and small
intestine prefer to use RAB27A and STX3 rather than RAB31 and YKT6 in mediating exosome biogenesis and CD44 for docking, presumably to make exosomes
more effective in propagating inflammation than adipose tissue macrophages. As cell-cell communication vehicles, exosomes propagate inflammation from first
inflammatory cells to secondary inflammatory cells [see also Figure 5 of our previous report for more evidence and the experimental data of others (PMID: 27842563)].
adaptive immune system such as T cells have an antigen-
specific memory function (64). However, recently it became
clear that innate immune cells also have trained immunity
(innate immune memory) functions in the form of increases in
three key metabolic pathways: glycolysis, acetyl-CoA synthesis,
and the mevalonate pathway (65). Thus, in addition to the
Frontiers in Immunology | www.frontiersin.org 22 November 2019 | Volume 10 | Article 2612
Lai et al. Novel Macrophage Pathways in Disease
FIGURE 5 | (A) Mechanism V: The macrophages from peritoneum, lung, liver, and spleen upregulate more bioenergetics pathway enzymes (immunometabolism
pathway) than adipose tissues, with a significantly increased pentose phosphate pathway, three significantly increased fatty acid-related pathways, and a decreased
glutamine pathway, and the macrophages from bone marrow express higher bioenergetics pathway enzymes than peritoneum, intestine, and adipose tissues (For
detailed expression data, see Figure S7). (B) Ingenuity Pathway Analysis of bioenergetics/immunometabolism pathway markers.
bioenergetics metabolic pathway analysis, we further examined
whether tissue Mϕ have differences in the expression of trained
immunity pathway enzymes. We hypothesize that the expression
of trained immunity pathway enzyme genes in Mϕ from
peripheral tissues such as lung, liver, spleen, and intestine is
higher in than that of ATMϕ. As shown in Table 1, we found
that 24 enzymes are involved in three pathways of trained
immunity functions including 14 enzymes in glycolysis, three
enzymes in acetyl-CoA generation, and 7 enzymes in the
mevalonate pathway (28, 66). As shown in Figure 6A, Mϕ in
peritoneal, lung, liver, spleen, and intestine upregulate higher
levels of 11 out of 24 enzymes in trained immunity pathways
in comparison to ATMϕ. In addition, Mϕ in peritoneal and
intestine and ATMϕ upregulate 2 out of 24 enzymes and
downregulate 14 out of 24 enzymes in comparison to BM Mϕ.
The Ingenuity Pathway Analysis showed, as seen in Figure 6B,
that the top two pathways involved in upregulation of trained
immunity enzymes in Mϕ are LPS/IL-1-mediated inhibition of
RXR function and stearate biosynthesis I. The top pathway
shared by peripheral Mϕ and ATMϕ upregulation enzymes
is acetyl-CoA biosynthesis III. The two pathways among the
top three pathways shared by peripheral Mϕ and BM Mϕ are
the superpathway of cholesterol biosynthesis and mevalonate
pathway I.
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FIGURE 6 | (A) Mechanism VI: The macrophages from peritoneum, lung, liver, and spleen upregulate more trained immunity (innate immune memory)-related
metabolic genes than that of adipose tissues, and the macrophages from peritoneum, small intestine, and adipose tissues upregulate more trained immunity-related
metabolic genes than bone marrow macrophages (For detailed expression data, see Figure S8). (B) Ingenuity pathway–Venn Diagram analyses show that the
macrophages (Mϕ) from peritoneum, lung, liver, spleen, and intestine upregulate more shared trained immunity regulators such as mevalonate pathway regulators
than Mϕ from bone marrow. (C) The expression changes of 19 new enzymes involved in intracellular immunometabolism pathways (IMPs) and trained immunity
pathways (TIPs) of M1 Mϕ and 6 new enzymes involved in IMPs and TIPs of M2 Mϕ may be the mechanisms underlying the higher M1 Mϕ proinflammatory status of
lung, liver, spleen, and intestine and the disease group-specific pathways and shared disease pathways (PMIDs:28381829; 27396447;26694790; 30679807;
28396078). The green boxes are bioenergetics pathways (Figure 5A), and the blue boxes are trained immunity pathways (A). SLC1A5, GLUT1, LDH, PDH, ACLY,
and CPT1A are mentioned in previous studies. However, IDH is found to decrease in M1, but not sure in M2. *25 others (bolded and underlined) are not found in the
reviews listed above.
Figure 6C summarizes the findings from Figure 5A (in the
green boxes) and Figure 6A (in the blue boxes) into a new map
related to the Mϕ metabolic pathways identified in M1 and M2.
We found that the 19 new enzyme expression changes (with
∗, bolded, and underlined) involved in immunometabolism
pathways and trained immunity pathways may be the
mechanisms underlying the higher M1 proinflammatory
status of lung, liver, spleen, and intestine. Also, we found that
six new enzyme changes in M2-related pathways may also be
the mechanisms underlying the higher M2 anti-inflammatory
status of adipose tissue Mϕ as well as the disease group-specific
pathways and shared disease pathways.
DISCUSSION
Macrophages play a key role in the pathogenesis of various
diseases including cardiovascular diseases (13), metabolic
diseases (14), infectious diseases (15), respiratory diseases (16),
digestive diseases (17), autoimmune diseases (18), and many
types of cancers (19, 20). However, it remained unclear whether
Mϕ use the same pathways and play the same roles or use disease-
specific pathways and play disease-specific roles in addition to
the shared roles and pathways. To address this question and also
to identify the potential mechanisms underlying this issue, we
performed a novel type of big—omics database mining analysis,
which we pioneered in 2004 (30). We have made the following
significant findings. (1) The expression of 31 Mϕ markers and
45 Mϕ TFs are modulated in eight groups comprising a total of
34 diseases including 10 types of cancers, and both shared and
disease-specific pathways for each group of disease/tumor have
been identified. To identify the potential mechanisms underlying
the Mϕ heterogeneity related to disease-group-specific pathways,
we examined several novel aspects of Mϕ. (2) The expression
of M1 Mϕ markers is higher in Mϕ in lung, liver, spleen, and
intestine compared to in lean adipose tissue Mϕ in physiological
conditions. (3) Pro-adipogenic transcription factors C/EBPα
and PPARγ and proinflammatory adipokine leptin upregulate
the expression of M1 Mϕ markers. Our results correlated
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well with a recent report implicating a pleiotropic protein
prohibitin in regulating adipose-immunometabolism (67). (4)
Immunologically peripheral tissue Mϕ from lung, liver, spleen,
intestine, and bone marrow express higher levels of T cell co-
inhibition/immune checkpoint receptor CD274 (programmed
death-ligand 1, PDL-1) among ten co-inhibition receptors than
that of lean adipose tissues, presumably to counteract the M1
dominant status via its reverse signaling and high homeostatic
and anti-inflammatory functions (52). Our results reveal a new
mechanism underlying the toxicities of the anti-PD-1 and anti-
PD-L1 immune checkpoint antibodies (68). (5) Tissue Mϕ
from lung, liver, spleen, intestine, and bone marrow prefer to
use RAB27A and STX3 than RAB31 and YKT6 in mediating
exosome biogenesis and docking, suggesting new inflammatory
exosome markers and a new inflammatory exosome status for
propagating inflammation from inflamed cells to secondary
inflammatory cells as we reported previously (25). Our results
correlated well with recent findings that inflammation leads
to distinct populations of extracellular vesicles (69). (6) To
address why Mϕ in peripheral tissues have a higher M1
status than those in adipose tissues, we found that Mϕ in
peritoneal, lung, liver, spleen, and intestine upregulate higher
levels of immunometabolism pathway enzymes than adipose
tissue Mϕ (ATMϕ). (7) To address the potential mechanism
underlying the higher M1 proinflammatory status of Mϕ in
peripheral tissues, we found that Mϕ from peritoneum, lung,
FIGURE 7 | A new working model. (A) Twenty novel disease group-specific-, and 12 new shared- macrophage pathways have been identified in eight groups of 34
diseases including 24 inflammatory organ diseases and 10 types of tumors as the phenotypic findings. (B) To identify potential mechanisms underlying the
macrophage phenotypes, we identified new tissue mechanisms that macrophages in peripheral tissues have higher M1 like pro-inflammatory status than lead adipose
tissue macrophages, which are controlled by high expression of the immune checkpoint/co-inhibition receptor CD274 via its reverse signaling. (C) We identified six
new cell and molecular mechanisms including three cell surface mechanisms, two groups of intracellular metabolism pathways and two groups of nuclear
transcription factors.
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liver, and spleen upregulate more trained immunity (innate
immune memory)-related metabolic genes than that of adipose
tissues and that the macrophages from peritoneum, small
intestine, and adipose tissues upregulate more trained immunity-
related metabolic genes than bone marrow macrophages.
Taken together, our results suggest that multiple mechanisms
such as those at the cell surface including M1 Mϕ markers,
cell-cell contact receptors, cell-cell communication exosomes,
intracellular immunometabolism and trained immunity, andMϕ
nuclear transcription factors may be responsible for the disease
group-specific pathways and shared pathways that we found in
eight groups of 34 diseases.
Since CD274 reverse signaling works via its interaction with
CD279 (PD1) expressed in CD4+ T cells, CD8+ T cells, B cells,
macrophages, and dendritic cells (70), these analyses emphasize
the following. (1) CD279+ T cells (both CD4+ and CD8+) and
B cells have significant innate immune functions in controlling
CD274+ Mϕ proinflammatory status and maintaining tissue
homeostasis in addition to having antigen-specific adaptive
immune functions. (2) T cell co-stimulation and co-inhibition
receptors serve as prototypic cell surface receptor-mediated
cell-cell contact signaling in addition to classical signaling
pathways from cytokine receptors, growth factor receptors,
pathogen-associated molecular pattern receptors (PAMP-Rs),
danger-associated molecular pattern receptors (DAMP-Rs), and
conditional DAMP-Rs, as we reported previously (12). (3) Our
results suggest a potential molecular mechanism underlying
the clinical finding that elevated immune-related adverse
effects (irAEs) of systematically injected anti-PD-L1 monoclonal
antibody (mAb) (Durvalumab) in patients with cancers (71).
Blocking CD274 reverse signaling could activate all the CD274+
tissue macrophages and contribute to elevated immune-related
adverse effects (irAEs). (4) Since CD279 is also expressed
in tumor-associated macrophages (TAMs) (72), our results
also suggest a possibility that CD279-CD274 interaction on
TAMs may suppress the anti-tumor functions of TAMs via
reverse signaling.
To summarize our findings, we have proposed a new working
model with three connected parts. Figure 7A illustrates the
first part: based on the expression levels of two groups of 31
Mϕ subset markers (9) and 45 Mϕ transcription factors in
the eight groups of 34 diseases (also see Table 2), we have
identified for the first time 20 novel Mϕ disease group-specific
pathways and 12 disease-shared pathways (shared in more than
four major disease groups). These results have demonstrated
two aspects for the first time. First, the pathogenesis of
various diseases and tumors significantly modulates Mϕ
signaling pathways in disease group-specific and shared
manners. Figure 7B illustrates the second: the potential tissue
mechanisms underlying the above-mentioned Mϕ heterogeneity
in diseased conditions. Based on the differential expression
of regulators including M1 markers, M1 TFs, co-stimulation
and co-inhibition/immune checkpoint receptors, cell-cell
communication exosome biogenesis machinery, M1 bioenergetic
enzymes, and trained immunity enzymes, we proposed a new
concept of tissue M1 Mϕ status. We found that first, Mϕs
in liver, small intestine, and bone marrow-derived Mϕ have
the highest macrophage inflammation potential and, second,
adipose tissue from lean animals and surprisingly spleen have
low Mϕ inflammation potential. Of note, white adipose tissue
hypertrophy recruits significant numbers of inflammatory cells
includingMϕ (73). The new data have demonstrated that various
tissue Mϕ have significant differences in M1 proinflammatory
status, which could be controlled by high expression of
a co-inhibition receptor such as CD274 (PDL1)-initiated
anti-inflammatory reverse signaling. It is noteworthy that each
tissue has its own composition of embryonically derived and
adult-derived Mϕ, but it is unclear whether the Mϕ of distinct
origins are functionally interchangeable or have unique roles
at steady state (74). These issues can be examined in the future
when new microarray/RNA-sequencing (RNA-Seq) data are
available. Figure 7C illustrates the third part of the model:
three novel major cell/molecular mechanisms underlying the
above-mentioned Mϕ heterogeneity in diseased conditions.
The six novel cell and molecular mechanisms include three
cell surface mechanisms (Mϕ subset markers with potential
of signaling, cell-cell interaction receptors (co-stimulation and
co-inhibition/immune checkpoint receptors), and inflammation-
modulating cell-cell communication exosomes), two new
metabolism mechanisms (the immunometabolism/bioenergistic
and trained immunity metabolic pathways), and, finally,
nuclear transcription factors. Taken together, the new tissue,
cell, and molecular mechanisms may contribute to the novel
Mϕ signaling heterogeneity in diseased conditions that we
have found.
We acknowledge that carefully designed in-vitro and in-
vivo experimental models will be needed to verify all the
results we report here. These experimental models will enable
the consolidation of the Mϕ disease group-specific pathways
in various pathological conditions. However, the big data
mining analyses that we pioneered in 2004 (30) have provided
significant insights into the Mϕ disease group-specific and
shared pathways and heterogeneity, homeostasis, and functions
of Mϕ in various diseases and cancers/tumors and have also
identified novel therapeutic targets for treating cancers/tumors
and inflammation, tissue regeneration, and tissue repair.
MATERIALS AND METHODS
Expression Profile of Mϕ Subset Markers,
Exosome Biogenesis Mediators, Exosome
Docking Mediators, Bioenergic Pathway
Enzymes, T Cell Co-stimulation and
Co-inhibition Receptors, and Mϕ
Transcription Factors in Mϕs
Microarray datasets were collected from the National Institutes
of Health (NIH)-National Center for Biotechnology Information
(NCBI) GEO DataSets (https://www.ncbi.nlm.nih.gov/gds/)
databases and analyzed with GEO2R (https://www.ncbi.nlm.
nih.gov/geo/geo2r/). The numbers of 11 GEO datasets in
non-diseased conditions are as follows: GSE56711, GSE85346,
GSE55760, GSE59585, GSE14004, GSE37514, GSE50183,
GSE66073, GSE46320, GSE27017, and GSE56711. The numbers
of 32 GEO datasets in diseased conditions are as follows:
GSE55235, GSE81622, GSE27335, GSE57376, GSE46451,
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GSE27411, GSE16879, GSE29507, GSE48080, GSE65517,
GSE40224, GSE19339, GSE23561, GSE57691, GSE23561,
GSE6088, GSE55100, GSE25724, GSE65204, GSE37768,
GSE53408, GSE48080, GSE45670, GSE79973, GSE74656,
GSE41657, GSE16515, GSE75037, GSE70951, GSE46602,
GSE36668, and GSE75038. The number of the GEO dataset in
gene knock-out mice is as follows: GSE40493.
As shown in Figure 1, 207 regulator genes in seven groups
were studied in this paper, including 31 Mϕ subset marker genes,
18 Mϕ subset transcription factor genes (TF), 27 Mϕ general
transcription factor genes (21), 28 T cell co-stimulation and co-
inhibition receptor genes, bioenergetics pathway enzymes genes
and trained immunity pathway gene numbers are totally 80. The
logic flow and rationale are explained in Figure 1 and Table 2.
We also analyzed the expression of four house-keeping genes for
all of the GEO datasets used. The house-keeping gene list was
extracted from a related report (74).
Genes with a more than 1.5-fold expression change were
defined as the upregulated genes, while genes with an
expression change of less than 1.5-fold were defined as
downregulated genes.
Ingenuity Pathway Analysis
We utilized Ingenuity Pathway Analysis (IPA, Ingenuity Systems,
http://pages.ingenuity.com/rs/ingenuity/images/IPA_data_
sheet.pdf) to characterize clinical relevance and molecular
and cellular functions related to the genes identified in our
microarray analysis. The differentially expressed genes were
identified and uploaded into IPA for analysis. The core and
pathways analysis was used to identify molecular and cellular
pathways, as we reported previously (25, 75, 76).
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